- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03522935
Subcutaneous Elafin in Healthy Subjects
Safety and Tolerability of Escalating Doses of Subcutaneous Elafin (Tiprelestat) Injection in Healthy Normal Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There will be a total of up to 30 subjects randomly assigned to 5 groups with 6 subjects in each group. One subject in each group will be assigned to placebo drug and 5 subjects to active drug. Subjects in each group will receive a single daily dose of Elafin/Placebo for total of 7 days. There will be ascending doses across groups. Groups receiving a higher dose will only do so after the previous group has completed dosing (i.e., 7 days). Each subject will be followed over a 28 day time period.
An interim trial analysis will occur after completion of the 2nd cohort in order for the research team to review PK and safety data to determine modification (if needed) of dosing strategy for groups 3-5. The study is also designed to absorb a de-escalation strategy. If the protocol requires a lowering of dose from the initial dosing, a new group will be assigned a low-dose subcutaneous Elafin regimen.
The study will conclude at any dose that produces clinically significant adverse effects and identified as Maximum Tolerated Dose (MTD).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Early Phase Research Unit (DEPRU)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
A subject will be eligible only if all of the following criteria apply:
- Male or female, 18 - 55 years of age
- No history or clinically relevant cardiovascular, renal, gastrointestinal, hepatic, metabolic, endocrine, neurological, or psychiatric abnormalities and is in general good health at screening examination.
- Normal or clinically acceptable ECG
- Normal blood pressure (systolic: 90 - 140 mmHg; diastolic: 50 - 90 mmHg) and heart rate (45 - 100 bpm)
- Body mass index of 18.0 - 32.0 (kg/m2)
- Ability to communicate well with the investigator and to comply with the requirements of the entire study.
- Informed consent.
Females of childbearing potential must use an acceptable form of contraception at time of enrollment (and throughout the duration of study) including, but not limited to the following:
- Documentation of surgical sterilization (bilateral tubal ligation, hysterectomy)
- Naturally postmenopausal (spontaneous cessation of menses) for at least 24 consecutive months prior to dosing on Day -1 and with an FSH level at screening of ≥ 40 mIU/mL
- Intrauterine Device (IUD) plus condom plus contraceptive sponge or foam or jelly
- Condom plus contraceptive sponge or foam or jelly
- Hormonal contraception (combination oral contraceptives, transdermal patch, injectables, implantables, or vaginal ring) *Subject is not of childbearing potential if the following criteria have been met:
- Hysterectomy > 1 month ago
- Bilateral oophorectomy > 1 month ago
- 45-50 years old AND LMP ≥ 24 months ago and documented FSH > 40mIU/mL
- Males must agree to use a barrier method of birth control from 30 days before first study drug administration until 90 days after last study drug administration.
Exclusion criteria:
A subject will not be eligible if any of the following criteria apply:
- Administration of any investigational drug 45 days prior to study enrollment.
- Active participation in another interventional clinical trial.
- Use of any prescription medication within 30 days (with exception to oral contraceptives) or over-the-counter medication (OTC) within 7 days before first study drug administration. Use of OTC medications may be permitted after day 1 visit until end of study with approval of the protocol investigator.
- Subject performed heavy physical exertion 2 days before eligibility assessment and before admission into clinical research center.
- Subject consumes more than 500 mL of beer/day or 250 mL of wine/day or 2 glasses of liquor/day.
- Subject has a history of chronic alcohol or drug abuse within the last 4 weeks.
- Subject smokes more than 10 cigarettes per day or has done so within 6 months prior to eligibility assessment.
- Subject has a diet that deviates notably from the "normal" amounts of protein, carbohydrate, and fat, as judged by the investigator (e.g., vegetarians or vegans).
- Subject consumes more than 600 mg of caffeine/day (200 mL of coffee contain approximately 100 mg of caffeine, 200 mL of black tea approximately 30 mg and 200 mL of soda approximately 20 mg).
- Subject has donated blood or had a comparable blood loss (>400 mL) within the last 3 months prior to eligibility assessment or anemia defined by hematocrit value less than 30% at screening.
- Subject has any clinically relevant abnormality in physical examination, vital signs and electrocardiogram (ECG).
- Serious adverse reaction or hypersensitivity to any drug.
- Inability to communicate or co-operate due to a language problem, poor mental development or impaired cerebral function.
- Females who are lactating or at risk of pregnancy.
- Presence of pain incurred by unknown causes.
- History of asthma or other respiratory disease.
- History of neurologic or neuromuscular disease.
- History of hypotension, hypertension or cardiovascular disease.
- History of gastrointestinal, hepatic, or renal disease and/or impairment.
- Positive urine drug screen for drugs with a high potential for abuse and low persistence in the urine.
- Subject with active or history of malignancy, known Hepatitis B or C, or HIV.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Elafin 0.03 mg/kg
5 subjects will be administered with 0.03 mg/kg of Elafin subcutaneously once daily for 7 days.
|
Elafin subcutaneous.
Other Names:
|
Experimental: Elafin 0.06 mg/kg
5 subjects will be administered with 0.06 mg/kg of Elafin subcutaneously once daily for 7 days.
|
Elafin subcutaneous.
Other Names:
|
Experimental: Elafin 0.10 mg/kg
5 subjects will be administered with 0.10 mg/kg of Elafin subcutaneously once daily for 7 days.
|
Elafin subcutaneous.
Other Names:
|
Experimental: Elafin 0.15 mg/kg
5 subjects will be administered with 0.15 mg/kg of Elafin subcutaneously once daily for 7 days.
|
Elafin subcutaneous.
Other Names:
|
Experimental: Elafin 0.18 mg/kg
5 subjects will be administered with 0.18 mg/kg of Elafin subcutaneously once daily for 7 days.
|
Elafin subcutaneous.
Other Names:
|
Placebo Comparator: Placebo Drug
5 subjects will be administered with placebo drug subcutaneously once daily for 7 days.
|
Placebo subcutaneous.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events in healthy controls.
Time Frame: 28 day time period
|
Safety and tolerability will be determined on the basis of adverse events reported and the severity of adverse events.
|
28 day time period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: AUC0-last
Time Frame: 28 day time period
|
AUC0-last: Area under the concentration time-curve to the last concentration above the lower limit of quantitation (after final dose consumed)
|
28 day time period
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: Cmax
Time Frame: 28 day time period
|
Cmax: Maximum observed concentration
|
28 day time period
|
Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: Tmax
Time Frame: 28 day time period
|
Tmax: Time of maximum observed concentration
|
28 day time period
|
Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: Ke
Time Frame: 28 day time period
|
Ke: Elimination rate constant
|
28 day time period
|
Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: AUC0-inf
Time Frame: 28 day time period
|
AUC0-inf: Area under the concentration time-curve extrapolated to infinit
|
28 day time period
|
Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: t½
Time Frame: 28 day time period
|
t½: Terminal elimination half-life
|
28 day time period
|
Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: CL/F
Time Frame: 28 day time period
|
CL/F: Apparent total clearance of the drug from plasma after oral administration
|
28 day time period
|
Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: V/F
Time Frame: 28 day time period
|
V/F: Oral volume of distribution
|
28 day time period
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 42336
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
Vanderbilt University Medical CenterRecruitingIdiopathic Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial Hypertension | Scleroderma Associated Pulmonary Arterial Hypertension | Appetite Suppressant Associate PAHUnited States
-
American Medical Association FoundationWithdrawnIdiopathic Pulmonary Arterial Hypertension.United States
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
Association de Recherche en Physiopathologie RespiratoireGlaxoSmithKline; Soladis; InterlisUnknownPulmonary Arterial Hypertension (PAH)France
-
Medical University of GrazLudwig Boltzmann Institute for Lung Vascular ResearchCompletedIdiopathic Pulmonary Arterial HypertensionAustria
-
Zhejiang UniversityCompletedIdiopathic Pulmonary Arterial HypertensionChina
-
Gachon University Gil Medical CenterChonbuk National University Hospital; Samsung Medical Center; Pusan National... and other collaboratorsUnknownPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Deep Phenotyping | Heritable Pulmonary Arterial HypertensionKorea, Republic of
-
ActelionWithdrawnArterial Hypertension, PulmonaryPoland, Germany
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on Elafin
-
EMD SeronoSanofiCompletedMelanoma | Breast Cancer | Colorectal Cancer | Non Small Cell Lung Cancer | Metastatic Solid Tumor | Locally Advanced Solid TumorUnited States, Italy, Spain
-
University of MiamiRecruitingBreast Cancer | Metastatic Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast CancerUnited States